Twelve-week monotherapy with the DPP-4 inhibitor vildagliptin improves glycemic control in subjects with type 2 diabetes

Hormone and Metabolic Research

Volumn 38, Issue 6, 2006, Pages 423-428

  Pratley, Richard E ^a   Jauffret Kamel, S ^b   Galbreath, E ^b   Holmes, D ^b  

^a UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Dipeptidyl peptidase IV; Efficacy; Glycemic control; Incretin

Indexed keywords

C PEPTIDE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCOSE; HEMOGLOBIN A1C; INSULIN; LIPID; PLACEBO; VILDAGLIPTIN;

ABDOMINAL PAIN; ADULT; AGED; ANXIETY; ARTICLE; BODY WEIGHT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC DIET; DIZZINESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DYSLIPIDEMIA; FATIGUE; FEMALE; GASTRITIS; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEADACHE; HEART PALPITATION; HUMAN; HYPERTENSION; HYPOGLYCEMIA; INSULIN RESPONSE; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SWEATING; THORAX PAIN;

ADAMANTANE; ADENOSINE DEAMINASE; ADULT; AGED; ANTIGENS, CD26; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; FEMALE; GLYCOPROTEINS; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; MALE; MIDDLE AGED; PLACEBOS; PROTEASE INHIBITORS;

EID: 33745903093     PISSN: 00185043     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2006-944546     Document Type: Article

References (17)

1. Ahren B, Larsson H, Holst JJ. Effects of glucagon-like peptide-1 on islet function and insulin sensitivity in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1997; 82: 473-478
2. Vella A, Rizza RA. Extrapancreatic effects of GIP and GLP-1. Horm Metab Res 2004; 36: 830-836
3. Zander M, Madsbad S, Madsen JL, Holst JJ. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and b-cell function in type 2 diabetes: a parallel-group study. Lancet 2002; 359: 824-830
4. Holst JJ, Orskov C. The incretin approach for diabetes treatment: modulation of islet hormone release by GLP-1 agonism. Diabetes 2004; 53 (suppl 3): S197-S204
5. Ahren B, Schmitz O. GLP-1 receptor agonists and DPP-4 inhibitors in the treatment of type 2 diabetes. Horm Metab Res 2004; 36: 867-876
6. Mentlein R, Gallwitz B, Schmidt WE. Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1 (7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur J Biochem 1993; 214: 829-835
7. Nauck MA. Glucagon-like Peptide 1 (GLP-1) in the treatment of diabetes. Horm Metab Res 2004; 36: 852-858
8. Amylin Pharmaceuticals, Inc. Byetta™ (exenatide injection) [Prescribing Information]. San Diego: Amylin Pharmaceuticals, Inc., 2005
9. Villhauer EB, Brinkman JA, Naderi GB et al. 1-[[(3-hydroxy-1-adamantyl) amino]acetyl]-2-cyano-(S)-pyrrolidine: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties. J Med Chem 2003; 46: 2774-2789
10. Mari A, Sallas WM, He YL et al. The dipeptidyl peptidase-IV inhibitor, vildagliptin, improves model-assessed b-cell function in patients with type 2 diabetes. J Clin Endocrinol Metab 2005; 90: 4888-4894
11. Ahren B, Pacini G, Foley JE, Schweizer A. Improved meal-related b-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over 1 year. Diabetes Care 2005; 28: 1936-1940
12. Ahren B, Landin-Olsson M, Jansson P-A et al. Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels and reduces glucagon levels in type 2 diabetes. J Clin Endocrinol Metab 2004; 89: 2078-2084
13. Ahren B, Gomis R, Standl E, Mills D, Schweizer A. Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes. Diabetes Care 2004; 27: 2874-2880
14. Matthews DR, Hosker JP, Rudenski AS et al. Homeostasis model assessment: insulin resistance and b-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-419
15. Sluiter WJ, Erkelens DW, Reitsma WD, Doorenbos H. Glucose tolerance and insulin release, a mathematical approach I. Assay of the beta-cell response after oral glucose loading. Diabetes 1976; 25: 241-244
16. Matsuda M, DeFronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 1999; 22: 1462-1470
17. Ahren B, Simonsson E, Larsson H et al. Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes. Diabetes Care 2002; 25: 869-875